🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 06/04/2005 | 9,14 | 9,74 | 9,12 | 9,50 | +5,44% | 6,78% | 691.400 |
| 05/04/2005 | 8,90 | 9,10 | 8,61 | 9,01 | +2,04% | 5,51% | 781.500 |
| 04/04/2005 | 9,20 | 9,30 | 8,75 | 8,83 | -2,97% | 5,98% | 662.000 |
| 01/04/2005 | 9,31 | 9,59 | 9,06 | 9,10 | -2,78% | 5,69% | 518.700 |
| 31/03/2005 | 9,45 | 9,45 | 9,21 | 9,36 | -1,06% | 2,54% | 451.300 |
| 30/03/2005 | 9,24 | 9,46 | 9,20 | 9,46 | +2,49% | 2,81% | 467.200 |
| 29/03/2005 | 9,60 | 9,84 | 9,20 | 9,23 | -4,25% | 6,67% | 618.700 |
| 28/03/2005 | 9,90 | 10,15 | 9,60 | 9,64 | -2,82% | 5,56% | 405.300 |
| 24/03/2005 | 9,97 | 10,13 | 9,85 | 9,92 | -0,40% | 2,81% | 217.800 |
| 23/03/2005 | 9,98 | 10,20 | 9,86 | 9,96 | -0,50% | 3,41% | 589.000 |
| 22/03/2005 | 10,14 | 10,19 | 9,93 | 10,01 | -0,79% | 2,56% | 508.100 |
| 21/03/2005 | 10,40 | 10,50 | 10,01 | 10,09 | -2,98% | 4,71% | 478.700 |
| 18/03/2005 | 10,39 | 10,57 | 10,27 | 10,40 | +0,39% | 2,89% | 1.048.600 |
| 17/03/2005 | 10,28 | 10,41 | 10,09 | 10,36 | +0,68% | 3,11% | 390.100 |
| 16/03/2005 | 10,27 | 10,50 | 10,24 | 10,29 | -0,48% | 2,53% | 348.200 |
| 15/03/2005 | 10,74 | 10,88 | 10,26 | 10,34 | -3,18% | 5,77% | 451.800 |
| 14/03/2005 | 10,11 | 10,75 | 10,11 | 10,68 | +5,33% | 6,33% | 550.600 |
| 11/03/2005 | 10,41 | 10,55 | 10,07 | 10,14 | -2,78% | 4,61% | 502.700 |
| 10/03/2005 | 10,33 | 10,71 | 10,33 | 10,43 | +0,77% | 3,68% | 569.800 |
| 09/03/2005 | 10,27 | 10,46 | 10,20 | 10,35 | +0,00% | 2,53% | 489.300 |
| 08/03/2005 | 10,47 | 10,54 | 10,28 | 10,35 | -0,77% | 2,48% | 792.700 |
| 07/03/2005 | 10,66 | 11,00 | 10,36 | 10,43 | -2,34% | 6,00% | 573.400 |
| 04/03/2005 | 11,54 | 11,55 | 10,66 | 10,68 | -6,72% | 7,71% | 756.400 |
| 03/03/2005 | 11,44 | 11,96 | 11,08 | 11,45 | +0,35% | 7,69% | 478.500 |
| 02/03/2005 | 11,66 | 11,89 | 11,30 | 11,41 | -2,81% | 5,06% | 565.400 |
| 01/03/2005 | 11,54 | 11,94 | 11,42 | 11,74 | +1,73% | 4,51% | 788.400 |
| 28/02/2005 | 11,88 | 11,99 | 11,34 | 11,54 | -3,75% | 5,47% | 718.800 |
| 25/02/2005 | 11,70 | 11,99 | 11,55 | 11,99 | +2,57% | 3,76% | 440.200 |
| 24/02/2005 | 11,41 | 11,70 | 11,23 | 11,69 | +1,74% | 4,12% | 570.700 |
| 23/02/2005 | 10,98 | 11,50 | 10,92 | 11,49 | +4,36% | 5,28% | 531.700 |